Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.38 |
| ▸ | NPY4R | P50391 | 5/20 | 0.38 |
| ▸ | NPY1R | P25929 | 4/20 | 0.38 |
| ▸ | NPY2R | P49146 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | FURIN | P09958 | 3/20 | 0.37 |
| ▸ | NMT2 | O60551 | 1/20 | 0.37 |
| ▸ | NMT1 | P30419 | 1/20 | 0.37 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18820346 | 0.94 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL9943152 | 0.94 | FAP (0.47) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL16266184 | 0.94 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL16266214 | 0.94 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL15246622 | 0.94 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL24520454 | 0.94 | FAP (0.47) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL20808481 | 0.94 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL21416485 | 0.94 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL16266215 | 0.94 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL3244447 | 0.94 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109942-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| US-20210030887-A1 | NON-NATURAL AMATOXIN-TYPE ANTIBODY CONJUGATE | SYSTIMMUNE, INC. | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030887-A1 | NON-NATURAL AMATOXIN-TYPE ANTIBODY CONJUGATE | CD47, ANPEP, NGLY1 | FAP 2220/4885NPY5R 3398/4885NPY4R 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.